Pages that link to "Q28367498"

The following pages link to Modification of CCNU pharmacokinetics by misonidazole--a major mechanism of chemosensitization in mice (Q28367498):

Displaying 28 items.

• Preclinical pharmacokinetics of benznidazole (Q28268944) (← links)
• Clinical pharmacokinetics of oral CCNU (lomustine) (Q28307850) (← links)
• Pharmacokinetic rationale for the interaction of 5-fluorouracil and misonidazole in humans (Q28366957) (← links)
• Sensitization of normal and malignant tissues to cyclophosphamide by nitroimidazoles with different partition coefficients (Q35991273) (← links)
• Misonidazole and CCNU: further evidence for a pharmacokinetic mechanism of chemosensitization and therapeutic gain (Q35991401) (← links)
• Enhancement of nitrosourea cytotoxicity by misonidazole in vitro: correlation with carbamoylating potential (Q35991428) (← links)
• Enhancement of melphalan-induced tumour cell killing by misonidazole: an interaction of competing mechanisms (Q35991532) (← links)
• In vitro potentiation of BCNU activity in rat brain tumour cells pretreated with misonidazole (Q35991687) (← links)
• Chemopotentiation in vivo: no loss of sensitization with fractionation (Q35991805) (← links)
• Effect of misonidazole pretreatment on nitrogen mustard-induced DNA cross-linking in mouse tissues in vivo (Q35992080) (← links)
• Chemopotentiation of CCNU metabolites by misonidazole (Q35992207) (← links)
• Chemosensitization by lipophilic nitroimidazoles (Q36047863) (← links)
• The effect of radiosensitizers on the pharmacokinetics of melphalan and cyclophosphamide in the mouse (Q36048084) (← links)
• Pharmacokinetic drug interactions of commonly used anticancer drugs. (Q38164714) (← links)
• Antibody-directed enzyme prodrug therapy (ADEPT). (Q40912787) (← links)
• Enhancement of misonidazole chemosensitization effect by mild local hyperthermia (Q41125218) (← links)
• 2-Nitroimidazole potentiation of nitrosourea induced cytotoxicity in subcutaneous implants of rat 9L brain tumor cells (Q41671844) (← links)
• Antitumour imidazotetrazines, Part IX. The pharmacokinetics of mitozolomide in mice (Q42052887) (← links)
• Altered pharmacokinetics in the mechanism of chemosensitization: effects of nitroimidazoles and other chemical modifiers on the pharmacokinetics, antitumour activity and acute toxicity of selected nitrogen mustards (Q42220644) (← links)
• Misonidazole protects mouse tumour and normal tissues from the toxicity of oral CCNU. (Q42374560) (← links)
• Potentiation of CCNU activity by misonidazole in metastases (Q44927267) (← links)
• Effect of administration schedules on the potentiation of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) by misonidazole in subcutaneous 9l tumors (Q68184469) (← links)
• Distribution of nitroimidazoles and L-phenylalanine mustard in mammary adenocarcinoma 16/C tumors (Q69443045) (← links)
• Twenty-fifth annual general meeting of the British Association for Cancer Research. Abstracts of invited and profferred papers (Q70372779) (← links)
• The advantageous use of hypoxic tumour cells in cancer therapy: Identical chemosensitization by metronidazole and misonidazole at moderately elevated temperatures (Q71961381) (← links)
• Nitroimidazoles as modifiers of nitrosourea pharmacokinetics (Q72825353) (← links)
• Potentiation of cisplatin activity by the bioreductive agent tirapazamine (Q74820554) (← links)
• Twenty-sixth annual general meeting of the British Association for Cancer Research (in conjunction with the European Organization for Research and Treatment for Cancer--Pharmacokinetics and Metabolism Group and the Drug Metabolism Group). March 24-2 (Q93610865) (← links)